Peptide Schedule
Follistatin-34417 residues (approx.)GNCWLRQAKNGRCQVLYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Follistatin-344 Dosage Calculator
Follistatin-344 is a naturally occurring glycoprotein that acts as a potent inhibitor of myostatin and activin — two TGF-beta superfamily members that put the brakes on muscle growth.
100mcg · Daily
Summary: Add 1mL BAC water to your 1mg vial. Draw to 10.0 units on a U-100 syringe for a 100mcg dose. This vial will last 10 doses.
Cycle Planner
Follistatin-344 Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~90 minutesDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Follistatin-344 Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 200mcg | Daily |
| Aggressive | 300mcg | Daily |
Note: Myostatin/activin inhibitor. FS-344 is cleaved in vivo to FS-315 (serum) and FS-288 (tissue-bound). Cycle 2 weeks on, 4 weeks off. Daily injection required due to short half-life. Use insulin syringe for accuracy at these low doses.
About Follistatin-344
Follistatin-344 is a naturally occurring glycoprotein that acts as a potent inhibitor of myostatin and activin — two TGF-beta superfamily members that put the brakes on muscle growth. When you inject FS-344, it's cleaved in vivo into two active forms: FS-315 (the circulating serum form) and FS-288 (which binds tightly to cell surfaces in muscle tissue). Both work by physically binding to myostatin and activin, preventing them from reaching their receptors on muscle cells. In animal studies, follistatin overexpression has produced some of the most dramatic muscle growth seen with any single intervention — mice showed 194-327% increases in muscle mass compared to controls. Gene therapy trials using AAV-delivered FS-344 in Becker muscular dystrophy patients showed measurable improvements in walking distance without serious adverse effects. It's worth noting that most impressive data comes from gene therapy delivery (continuous follistatin expression) rather than daily subcutaneous injection. The peptide form requires daily dosing because of its short ~90-minute half-life, and whether brief daily spikes produce the same degree of myostatin inhibition as continuous expression is an open question. There's also emerging research on follistatin's role in hair regrowth through Wnt/beta-catenin signaling and potential anti-fibrotic effects in liver tissue, though these applications are even more preliminary.